Seeking Alpha

Shares of MannKind (MNKD +11%) go on a tear after the firm announces a plan to offer $370M in...

Shares of MannKind (MNKD +11%) go on a tear after the firm announces a plan to offer $370M in senior secured discount notes to be used in part to develop Phase 3 clinical trials of its AFREZZA product. The move follows up last month's FDA clearance on late-stage trials for the inhaled insulin therapy.
From other sites
Comments (1)
  • vtstuart
    , contributor
    Comments (123) | Send Message
     
    Hooray! Money to see them through resubmission.
    23 Sep 2011, 03:28 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs